Chemokine receptor antagonists: A novel therapeutic approach in allergic diseases

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 59, Issue 12, 2004, Pages 1243-1258

  Elsner, Jörn ^a,b   Escher, S E ^a   Forssmann, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b IPF PHARMACEUTICALS GMBH   (Germany)

Author keywords

Asthma; Atopic dermatitis; Chemokine; Chemokine receptor; Eosinophils

Indexed keywords

1 (1 CYCLOOCTENYL) 1 ETHYL 4 (2,7 DICHLOROXANTHENE 9 CARBOXAMIDO)PIPERIDINIUM IODIDE; 1 (1 CYCLOOCTENYLMETHYL) 4 (2,7 DICHLOROXANTHEN 9 YLCARBOXAMIDO) 1 ETHYLPIPERIDINIUM IODIDE; A 122057; A 122058; AOP RANTES; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR3; COMPOUND 115; COMPOUND 25; COMPOUND 26; COMPOUND 766994; COMPOUND X; CYSTEINYLPROLYLTRYPTOPHYLTYROSYLPHENYLALANYLTRYPTOPHYLPROLYLCYSTEINE; DPC 168; DPCA 37818; EOTAXIN; EOTAXIN[3-74]; GLYCOSAMINOGLYCAN; I TAC E0H1; LIGAND; MET CKBETA7; MET RANTES; N [1 (3,4 DICHLOROBENZYL)PIPERIDIN 4 YL](6 AMINO 2 BENZOTHIAZOLYLTHIO)ACETAMIDE; PEPTIDE; RANTES; RANTES[3-68]; RECEPTOR BLOCKING AGENT; RO 116 9132 238; SB 328437; SUBSTANCE 2Q; UCB 35625; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ATOPIC DERMATITIS; BASOPHIL; BINDING SITE; CELL INTERACTION; CELL TYPE; CLINICAL TRIAL; DRUG EFFECT; DRUG STRUCTURE; EOSINOPHILIA; HUMAN; LIGAND BINDING; MAST CELL; MEDIATOR; OLIGOMERIZATION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SKIN ALLERGY; TH2 CELL;

AMINO ACID SEQUENCE; ANIMALS; CHEMOKINES; CHEMOKINES, CC; CHEMOTACTIC FACTORS, EOSINOPHIL; GLYCOSAMINOGLYCANS; HUMANS; HYPERSENSITIVITY; LIGANDS; MOLECULAR SEQUENCE DATA; RANTES; RECEPTORS, CHEMOKINE;

EID: 8644254156     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00710.x     Document Type: Review

References (108)

1. GERARD C, ROLLINS BJ. Chemokines and disease. Nat Immunol 2001;2:108-115.
2. LUSTER AD. Antichemokine immunotherapy for allergic diseases. Curr Opin Allergy Clin Immunol 2001;1:561-567.
3. ZLOTNIK A, YOSHIE O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127.
4. BAGGIOLINI M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
5. MURPHY PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002;54:227-229.
6. LOETSCHER P, CLARK-LEWIS I. Agonistic and antagonistic activities of chemokines. J Leukoc Biol 2001;69:881-884.
7. LOETSCHER P, PELLEGRINO A, GONG JH, MATTIOLI I, LOETSCHER M, BARDI G et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001;276:2986-2991.
8. WENG Y, SICILIANO SJ, WALDBURGER KE, SIROTINA-MEISHER A, STARUCH MJ, DAUGHERTY BL et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem 1998;273:18288-18291.
9. OGILVIE P, PAOLETTI S, CLARK-LEWIS I, UGUCCIONI M. Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 2003;102:789-794.
10. OGILVIE P, BARDI G, CLARK-LEWIS I, BAGGIOLINI M, UGUCCIONI M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 2001;97: 1920-1924.
11. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Allergy Statistics. Factsheets, 2002. http://www.niaid. nih.gov/fact-sheets/allergystat.htm.
12. BUSSE WW, LEMANSKE RF. Review articles: Advances in immunology: asthma. N Engl J Med 2001;344:350-362.
13. O'BYRNE P, INMAN M, PARAMESWARAN K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108: 503-508.
14. YING S, MENG Q, ZEIBECOGLOU K, ROBINSON DS, MACFARLANE A, HUMBERT M et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1999;163:6321-6329.
15. LILLY CM, NAKAMURA H, BELOSTOTSKY OI, HALEY KJ, GARCIA-ZEPEDA EA, LUSTER AD et al. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001;163:1669-1675.
16. ELSNER J, KAPP A, VIRCHOW JC JR., LUTTMANN W. Eosinophils: Quo vadis? The role of eosinophils in the chemokine network of allergy. Mod Asp Immunobiol 2001;2:18-24.
17. ROBINSON DS, KAY AB, WARDLAW AJ. Eosinophils. Clin Allergy Immunol 2002;16:43-75.
18. TERZANO C, LAURENDI G, CAPOCCETTA G, RAPISARDA M, PACILIO R, PETROIANNI A. The smooth muscle and airway hyperresponsiveness. Eur Rev Med Pharmacol Sci 2003;7:9-26.
19. HUMBLES AA, LU B, NILSSON CA, LILLY C, ISRAEL E, FUJIWARA Y et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000;406:998-1001.
20. ANDREADIS AA, HAZEN SL, COMHAIR SA, ERZURUM SC. Oxidative and nitrosative events in asthma. Free Radic Biol Med 2003;35:213-225.
21. WARDLAW AJ. Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol 1999;104:917-926.
22. BURGEL PR, LAZARUS SC, TAM DC, UEKI IF, ATABAI K, BIRCH M et al. Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation. J Immunol 2001;167: 5948-5954.
23. ZIMMERMANN N, HERSHEY GK, FOSTER PS, ROTHENBERG ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 2003;111:227-242.
24. POPE SM, BRANDT EB, MISHRA A, HOGAN SP, ZIMMERMANN N, MATTHAEI KI et al. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 2001;108:594-601.
25. SCHMID-GRENDELMEIER P, ALTZNAUER F, FISCHER B, BIZER C, STRAUMANN A, MENZ G et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002;169:1021-1027.
26. MATTES J, YANG M, MAHALINGAM S, KUEHR J, WEBB DC, SIMSON L et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002;195:1433-1444.
27. HAHN C, TEUFEL M, HERZ U, RENZ H, ERB KJ, WOHLLEBEN G et al. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol 2003;111:1361-1369.
28. LECKIE MJ, TEN BRINKE A, KHAN J, DIAMANT Z, O'CONNOR BJ, WALLS CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
29. MENZIES-GOW A, FLOOD-PAGE P, SEHMI R, BURMAN J, HAMID Q, ROBINSON DS et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003;111:714-719.
30. KIPS JC, O'CONNOR BJ, LANGLEY SJ, WOODCOCK A, KERSTJENS HA, POSTMA DS et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-1659.
31. FLOOD-PAGE PT, MENZIES-GOW AN, KAY AB, ROBINSON DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
32. FLOOD-PAGE P, MENZIES-GOW A, PHIPPS S, YING S, WANGOO A, LUDWIG MS et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-1036.
33. KAY AB, MENZIES-GOW A. Eosinophils and interleukin-5: the debate continues. Am J Respir Crit Care Med 2003;167:1586-1587.
34. MA W, BRYCE PJ, HUMBLES AA, LAOUINI D, YALCINDAG A, ALENIUS H et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002;109:621-628.
35. HUMBLES AA, LU B, FRIEND DS, OKINAGA S, LORA J, AL GARAWI A et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002;99:1479-1484.
36. SIMON HU. Regulation of eosinophil and neutrophil apoptosis - similarities and differences. Immunol Rev 2001;179:156-162.
37. WEDI B, RAAP U, LEWRICK H, KAPP A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997;100:536-543.
38. BECK LA, DALKE S, LEIFERMAN KM, BICKEL CA, HAMILTON R, ROSEN H et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol 1997;159:2962-2972.
39. YING S, ROBINSON DS, MENG Q, BARATA LT, MCEUEN AR, BUCKLEY MG et al. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999;163:3976-3984.
40. MENZIES-GOW A, YING S, SABROE I, STUBBS VL, SOLER D, WILLIAMS TJ et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002;169:2712-2718.
41. FERNVIK E, GRONNEBERG R, LUNDAHL J, RAUD J, ZETTERSTROM O, HAGE-HAMSTEN M et al. Characterization of eosinophils and detection of eotaxin in skin chamber fluid after challenge with relevant allergen in patients with mild asthma. Clin Exp Allergy 1999;29: 1516-1525.
42. SATOH T, CHEN QJ, SASAKI G, YOKOZEKI H, KATAYAMA I, NISHIOKA K. Cyclophosphamide-induced blood and tissue eosinophilia in contact sensitivity: mechanism of hapten-induced eosinophil recruitment into the skin. Eur J Immunol 1997;27:85-91.
43. PLOTZ SG, SIMON HU, DARSOW U, SIMON D, VASSINA E, YOUSEFI S et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:2334-2339.
44. TEIXEIRA MM, WELLS TN, LUKACS NW, PROUDFOOT AE, KUNKEL SL, WILLIAMS TJ et al. Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest 1997;100:1657-1666.
45. TERADA N, HAMANO N, KIM WJ, HIRAI K, NAKAJIMA T, YAMADA H et al. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001;164:575-579.
46. LEONARDI A, JOSE PJ, ZHAN H, CALDER VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003;110:487-492.
47. LUKACS NW, MILLER AL, HOGABOAM CM. Chemokine receptors in asthma: searching for the correct immune targets. J Immunol 2003;171:11-15.
48. MITCHELL TJ, WALLEY AJ, PEASE JE, VENABLES PJ, WILTSHIRE S, WILLIAMS TJ et al. Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet 2000;356:1491-1492.
49. SRIVASTAVA P, HELMS PJ, STEWART D, MAIN M, RUSSELL G. Association of CCR5Delta32 with reduced risk of childhood but not adult asthma. Thorax 2003;58:222-226.
50. LUKACS NW, BERLIN A, SCHOLS D, SKERLJ RT, BRIDGER GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyper-reactivity. Am J Pathol 2002;160:1353-1360.
51. LUKACS NW, PROSSER DM, WIEKOWSKI M, LIRA SA, COOK DN. Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J Exp Med 2001:194:551-555.
52. GOYA I, VILLARES R, ZABALLOS A, GUTIERREZ J, KREMER L, GONZALO JA et al. Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. J Immunol 2003;170:2138-2146.
53. PONATH PD, QIN S, POST TW, WANG J, WU L, GERARD NP et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996;183:2437-2448.
54. OCHI H, HIRANI WM, YUAN Q, FRIEND DS, AUSTEN KF, BOYCE JA. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 1999;190:267-280.
55. SALLUSTO F, MACKAY CR, LANZAVECCHIA A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997;277:2005-2007.
56. UGUCCIONI M, MACKAY CR, OCHENS-BERGER B, LOETSCHER P, RHIS S, LAROSA GJ et al. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, mcp-4, and other chemokines. J Clin Invest 1997;100:1137-1143.
57. ELSNER J, MACK M, BRUHL H, DULKYS Y, KIMMIG D, SIMMONS G et al. Differential activation of CC chemokine receptors by AOP-RANTES. J Biol Chem 2000;275:7787-7794.
58. FORSSMANN U, MAGERT HJ, ADERMANN K, ESCHER SE, FORSSMANN WG. Hemofiltrate CC chemokines with unique biochemical properties: HCC-1/ CCL14a and HCC-2/CCL15. J Leukoc Biol 2001;70:357-366.
59. FORSSMANN U, UGUCCIONI M, LOETSCHER P, DAHINDEN CA, LANGEN H, THELEN M et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997;185:2171-2176.
60. ELSNER J, PETERING H, KLUTHE C, KIMMIG D, SMOLARSKI R, PONATH P et al. Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils. Eur J Immunol 1998;28:2152-2158.
61. DULKYS Y, SCHRAMM G, KIMMIG D, KNOSS S, WEYERGRAF A, KAPP A et al. Detection of mRNA for eotaxin-2 and eotaxin-3 in human dermal fibroblasts and their distinct activation profile on human eosinophils. J Invest Dermatol 2001;116:498-505.
62. ZIMMERMANN N, CONKRIGHT JJ, ROTHENBERG ME. CC chemokine receptor-3 undergoes prolonged ligand-induced internalization. J Biol Chem 1999;274:12611-12618.
63. DULKYS Y, KLUTHE C, BUSCHERMOHLE T, BARG I, KNOSS S, KAPP A et al. IL-3 induces down-regulation of CCR3 protein and mRNA in human eosinophils. J Immunol 2001;167:3443-3453.
64. CRUMP MP, RAJARATHNAM K, KIM KS, CLARK-LEWIS I, SYKES BD. Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation. J Biol Chem 1998;273:22471-22479.
65. GONG JH, UGUCCIONI M, DEWALD B, BAGGIOLINI M, CLARK LEWIS I. RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem 1996;271:10521-10527.
66. SKELTON NJ, ASPIRAS F, OGEZ J, SCHALL TJ. Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry 1995;34:5329-5342.
67. PAKIANATHAN DR, KUTA EG, ARTIS DR, SKELTON NJ, HEBERT CA. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 1997;36:9642-9648.
68. YE J, KOHLI LL, STONES MJ. Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3. J Biol Chem 2000;275:27250-27257.
69. MIDDLETON J, PATTERSON AM, GARDNER L, SCHMUTZ C, ASHTON BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002;100:3853-3860.
70. KUSCHERT GS, COULIN F, POWER CA, PROUDFOOT AE, HUBBARD RE, HOOGEWERF AJ et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999;38: 12959-12968.
71. CULLEY FJ, FADLON EJ, KIRCHEM A, WILLIAMS TJ, JOSE PJ, PEASE JE. Proteoglycans are potent modulators of the biological responses of eosinophils to chemokines. Eur J Immunol 2003;33:1302-1310.
72. PROUDFOOT AE, FRITCHLEY S, BORLAT F, SHAW JP, VILBOIS F, ZWAHLEN C et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001;276:10620-10626.
73. ALI S, FRITCHLEY SJ, CHAFFEY BT, KIRBY JA. Contribution of the putative heparan sulfate-binding motif BBXB of RANTES to transendothelial migration. Glycobiology 2002;12:535-543.
74. PROUDFOOT AE, HANDEL TM, JOHNSON Z, LAU EK, LIWANG P, CLARK-LEWIS I et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003;100:1885-1890.
75. SABROE I, CONROY DM, GERARD NP, LI Y, COLLINS PD, POST TW et al. Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3: blockade using a monoclonal antibody in vivo. J Immunol 1998;161:6139-6147.
76. HEATH H, QIN S, RAO P, WU L, LAROSA G, KASSAM N et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997;99:178-184.
77. PROUDFOOT AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002;2:106-115.
78. SCHWARZ MK, WELLS TN. New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 2001;1:347-358.
79. STRUYF S, DE MEESTER I, SCHARPE S, LENAERTS JP, MENTEN P, WANG JM et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 1998;28:1262-1271.
80. PROUDFOOT AE, POWER CA, HOOGEWERF AJ, MONTJOVENT MO, BORLAT F, OFFORD RE. et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-2603.
81. SIMMONS G, CLAPHAM PR, PICARD L, OFFORD RE, ROSENKILDE MM, SCHWARTZ TW et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
82. MOSIER DE, PICCHIO GR, GULIZIA RJ, SABBE R, POIGNARD P, PICARD L et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999;73:3544-3550.
83. ELSNER J, PETERING H, HOCHSTETTER R, KIMMIG D, WELLS TN, KAPP A et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol 1997;27:2892-2898.
84. GONZALO JA, LLOYD CM, WEN D, ALBAR JP, WELLS TN, PROUDFOOT A et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998;188:157-167.
85. MENTLEIN R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.
86. STRUYF S, PROOST P, SCHOLS D, DE CLERCQ E, OPDENAKKER G, LENAERTS JP et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162: 4903-4909.
87. NIBBS RJ, SALCEDO TW, CAMPBELL JD, YAO XT, LI Y, NARDELLI B et al. C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap. J Immunol 2000;164:1488-1497.
88. FULKERSON PC, ZIMMERMANN N, BRANDT EB, MUNTEL EE, DOEPKER MP, KAVANAUGH JL et al. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). Proc Natl Acad Sci USA 2004;101:1987-1992.
89. HOUIMEL M, LOETSCHER P, BAGGIOLINI M, MAZZUCCHELLI L. Functional inhibition of CCR3-dependent responses by peptides derived from phage libraries. Eur J Immunol 2001;31:3535-3545.
90. HARTLEY O, DORGHAM K, PEREZ-BERCOFF D, CERINI F, HEIMANN A, GAERTNER H et al. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J Virol 2003;77:6637-6644.
91. FORSSMANN U, HARTUNG I, BÄLDER R, FUCHS B, ESCHER SE, SPODSBERG N et al. NNY-CCL14, a potent CCL14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation. J Immunol 2004;173: 3456-3466.
92. BERTRAND CP, PONATH PD. CCR3 blockade as a new therapy for asthma. Expert Opin Investig Drugs 2000;9: 43-52.
93. FERNANDEZ-BOTRAN R. A small-molecule antagonist of human and murine CCR1 receptors. Expert Opin Investig Drugs 2001;10:1387-1389.
94. NAYA A, SAGARA Y, OHWAKI K, SAEKI T, ICHIKAWA D, IWASAWA Y et al. Design, synthesis, and discovery of a novel CCR1 antagonist. J Med Chem 2001;44:1429-1435.
95. NAYA A, KOBAYASHI K, ISHIKAWA M, OHWAKI K, SAEKI T, NOGUCHI K et al. Structure-activity relationships of 2-(benzothiazolylthio)acetamide class of CCR3 selective antagonist. Chem Pharm Bull (Tokyo) 2003;51:697-701.
96. SAEKI T, OHWAKI K, NAYA A, KOBAYASHI K, ISHIKAWA M, OHTAKE N et al. Identification of a potent and nonpeptidyl ccr3 antagonist. Biochem Biophys Res Commun 2001;281: 779-782.
97. SABROE I, PECK MJ, VAN KEULEN BJ, JORRITSMA A, SIMMONS G, CLAPHAM PR et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 2000;275:25985-25992.
98. DHANAK D, CHRISTMANN LT, DARCY MG, KEENAN RM, KNIGHT SD, LEE J et al. Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2. Bioorg Med Chem Lett 2001;11:1445-1450.
99. DHANAK D, CHRISTMANN LT, DARCY MG, JUREWICZ AJ, KEENAN RM, LEE J et al. Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1. Bioorg Med Chem Lett 2001;11:1441-1444.
100. WHITE JR, LEE JM, DEDE K, IMBURGIA CS, JUREWICZ AJ, CHAN G et al. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J Biol Chem 2000;275:36626-36631.
101. GlaxoSmithKline. Product development pipeline December 2003. http://science.gsk.com/pipeline/pipeline-dec2003.pdf, 2003
102. BRYAN SA, JOSE PJ, TOPPING JR, WILHELM R, SODERBERG C, KERTESZ D et al. Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med 2002;165:1602-1609.
103. BAO J. Pyrrolidine antagonists of the CCR3 chemokine receptors. Tech Rep 2003;8:http://www.albmolecular.com/features/tekreps/vo108/no03/.
104. WARRIOR U, MCKEEGAN EM, ROTTINGHAUS SM, GARCIA L, TRAPHAGEN L, GRAYSON G et al. Identification and characterization of novel antagonists of the CCR3 receptor. J Biomol Screen 2003;8:324-331.
105. WACKER DA, SANTELLA JB, GARDNER DS, VARNES JG III, ESTRELLA M, DELUCCA GV et al. CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships. Bioorg Med Chem Lett 2002;12:1785-1789.
106. DE LUCCA GV, KIM UT, JOHNSON C, VARGO BJ, WELCH PK, COVINGTON M et al. Discovery and structure-activity relationship of N-(ureidoalkyl)- benzylpiperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. J Med Chem 2002;45:3794-3804.
107. DALE DC, COTTLE TE, FIER CJ, BOLYARD AA, BONILLA MA, BOXER LA et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003;72:82-93.
108. NG T, MARX G, LITTLEWOOD T, MACDOUGALL I. Recombinant erythropoietin in clinical practice. Postgrad Med J 2003;79:367-376.